HCPCS Level II
Q5128
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg
Codes near Q5128
These sit next to Q5128 in the CMS Level II file. All Q codes
- Q5123Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
- Q5124Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg
- Q5125Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
- Q5126Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
- Q5127Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg
- Q5129Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg
- Q5130Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg
- Q5131Injection, adalimumab-aacf (idacio), biosimilar, 20 mg
- Q5132Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg
- Q5133Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 61314-0624-94 | Cimerli | Sandoz Inc. | 3 |
| 61314-0625-94 | Cimerli | Sandoz Inc. | 5 |
| 70114-0440-01 | Cimerli | Sandoz Inc. | 3 |
| 70114-0441-01 | Cimerli | Sandoz Inc. | 5 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.